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Background: A higher prevalence of coronary heart disease (CHD) in people with diabetes. We investigated the
high-density lipoprotein (HDL) subclass profiles and alterations of particle size in CHD patients with diabetes or
without diabetes.
Methods: Plasma HDL subclasses were quantified in CHD by 1-dimensional gel electrophoresis coupled with
immunodetection.
Results: Although the particle size of HDL tend to small, the mean levels of low density lipoprotein cholesterol
(LDL-C) and total cholesterol (TC) have achieved normal or desirable for CHD patients with or without diabetes
who administered statins therapy. Fasting plasma glucose (FPG), triglyceride (TG), TC, LDL-C concentrations, and
HDL3 (HDL3b and 3a) contents along with Gensini Score were significantly higher; but those of HDL-C, HDL2b+preβ2,
and HDL2a were significantly lower in CHD patients with diabetes versus CHD patients without diabetes; The preβ1-
HDL contents did not differ significantly between these groups. Multivariate regression analysis revealed that
Gensini Score was significantly and independently predicted by HDL2a, and HDL2b+preβ2.
Conclusions: The abnormality of HDL subpopulations distribution and particle size may contribute to CHD risk in
diabetes patients. The HDL subclasses distribution may help in severity of coronary artery and risk stratification,
especially in CHD patients with therapeutic LDL, TG and HDL levels.
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The diabetes is a major contributor to coronary artery
disease (CAD) morbidity and mortality. It has been
reported that adults with diabetes are at a 2- to 4-fold
increased risk of CAD events relative to those without
DM [1-5] and are at about 60% increased risk of early
mortality [6]. Features of the well documented “athero-
genic lipid pattern”, characterized by lowered high-
density lipoprotein cholesterol (HDL-C), and elevated
serum triglycerides (TG) [7], are presented in diabetic* Correspondence: Apolipoprotein2009@yahoo.com.cn
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reproduction in any medium, provided the orindividuals. On the other hand, it is well established that
plasma concentrations of HDL-C are inversely correlated
with the risk of atherosclerosis and cardiovascular dis-
ease (CVD) [8].
HDL particles are heterogeneous in size and compos-
ition. Using 1-dimensional gel electrophoresis and im-
munoblotting, HDL can be subdivided into preβ1-HDL,
HDL3c, HDL3b, and HDL3a as well as HDL2a and
HDL2b+preβ2-HDL. Despite the substantial epidemiological
data suggesting a cardioprotective role for HDL, much
remains unknown about the anti-atherothrombogenic
properties of different particles that comprise this class
of lipoproteins [9]. CHD patients often have increased
small discoidal HDL particles and decreased large α-1
and α-2 HDL particles [10]. The preβ1-HDL was identi-
fied as a novel and independent predictor of myocardial
infarction (MI) above and beyond traditional CHD risk. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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size was associated with an increased CHD risk, but this
association was largely explained by traditional risk fac-
tors [12]. The progressive insulin resistance(IR) was
associated a decrease in HDL size as a result of deple-
tion of large HDL2a and HDL2b particles and a modest
increase in small HDL. The HDL subclass pattern is
consistent with impaired reverse cholesterol transport
(RCT) in IR individuals [13]. Considering that high-risk
individuals are often treated with statins, development of
diagnostic and treatment strategies to study and target
HDL metabolism must involve not only the absolute
concentration of HDL-C, but also the functional proper-
ties of HDL particles [14]. Which might provide more
useful information for risk stratification in potentially
high-risk individuals and particularly in those patients
treated with lipid-altering therapy. In this study, we
examined the HDL subclasses distribution profile in
CHD patients with or without diabetes by one-
dimensional gradient gel electrophoresis.
Subjects and methods
Subjects
Two hundred and twelve patients with established CHD
participated in this study (These patients who were hos-
pitalized in cardiovascular department of West China
Hospital, Sichuan University). Quantitative coronary
angiography (QCA) was performed at the Cardiology
Department of the West China Hospital, Sichuan Uni-
versity. Diagnosis was based on clinical history and was
confirmed by QCA. The results of angiographic examin-
ation were regarded positive for coronary atherosclerosis
only if one or more major coronary arteries (right coron-
ary, left main coronary, left anterior descending, and cir-
cumflex) had at least 50% stenosis of the luminal area.
All angiograms were evaluated by two experienced phy-
sicians blinded to the study, and the severity of coronary
artery disease was assessed by using the Gensini score
system [15] which grades narrowing of the lumens of
the coronary arteries as: 1 for 1–25% narrowing, 2 for
26–50% narrowing, 4 for 51–75%, 8 for 76–90%, 16 for
91–99% and 32 for a completely occluded artery. This
score is then multiplied by a factor according to the im-
portance of the coronary artery as follows: 5 for a left
main stem (LMS) lesion, 2.5 for proximal left anterior
descending artery (LAD) and proximal circumflex artery
(CX) lesions, 1.5 for a mid-LAD lesion, and 1 for distal
LAD, mid/distal CX and right coronary artery lesions.
The multiplication factor for any other branch is 0.5. Fe-
male subjects were only included in the study if they
were postmenopausal or surgically sterile. According to
the World Health Organization (WHO) 1999 criteria
[16], a person with a prior history of diabetes was classi-
fied as previously diagnosed diabetes regardless of theglucose levels, and Exclusion criteria included: unstable/
uncontrolled clinically significant diseases, uncontrolled
primary hypothyroidism, nephrotic syndrome, renal dys-
function, or clinically significant hematology abnormal-
ities. Additional exclusion criteria were the presence of
active liver disease or hepatic dysfunction, consumption
of more than 14 alcoholic drinks per week, immunosup-
pressive agents, and smoked cigarettes. Patients were
maintained on other medications throughout the study,
with no change, including calcium channel blockers,
beta blockers, glucose-lowering, diuretics and other anti-
hypertensive therapy. Written informed consent was
obtained from the patients for publication of this report
and any accompanying images.
150 patients with CHD receive atorvastatin treatment
at 20 mg/day for 4 weeks, and other 62 CHD patients
receive simvastatin at 40 mg/day for 3 weeks. Blood
samples were collected from subjects, after a 12 h over-
night fast, into tubes containing 0.1% EDTA.
Blood samples
Fasting blood samples were collected into tubes contain-
ing EDTA before the percutaneous intervention and cen-
trifuged at 3000 rpm for 20 min at 4°C to obtain plasma.
Then it was stored at 4°C and used within 24 h for lipid
and apolipoprotein analyses. An aliquot of plasma was
stored at −70°C for the determination of HDL subclasses.
Plasma lipid and apolipoprotein analyses
Fasting plasma concentrations of TG and total choles-
terol (TC), HDL-C, and low density lipoprotein choles-
terol (LDL-C) along with FPG, apoA-I, apoB-100 values
were measured using automated standardized by Clinical
Laboratory of West China Hospital, Sichuan University.
HDL subclasses analyses
ApoA-I contents of plasma HDL subclasses were deter-
mined by 1-dimensional gel electrophoresis coupled with
immunodetection for apoA-I which developed and
modified at the Laboratory of Endocrinology and Metab-
olism, West China Hospital, Sichuan University.
Materials and equipment
The acrylamide was obtained from Serva, TRIS from
CA, bisacrylamide, boric acid, ammonium persulfate, su-
crose and TEMED from Merck, PVDF membrane from
Millipore. The gel apparatus included the BioRAD Mini-
PROTEAN 3 system, the LKB gradient maker, the LKB
peristaltic pump, the BioRAD thermostatic circulator.
Nondenaturing Polyacrylamide GGE of HDL
Gel casting
Polyacrylamide gradient gels were cast using a 2-chamber
gradient mixer. The Casting Frame, when placed on the
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the Short Plate together to form the gel cassette sandwich
prior to casting (BioRAD Mini-PROTEAN 3 system ,1.0-
mm spacers, 10-well combs). Then, 3.5 ml of the 2%acryl-
amide solution and 3.5 ml of a 30% acrylamide solution
were poured into the 2 chambers of the gradient mixer.
The acrylamide gradient was formed by allowing the gradi-
ent mixture to fill the gel casting cassette from the bottom
during by hydrostatic pressure. The Casting Stand secures
the Gel Cassette Assembly during gel casting. When the
gradient had been formed, 1 ml of distilled water was added
manually. The distilled water was added slowly with a Pip-
ette Pasteur, taking extreme care to keep a constant flow
and to avoid any stirring of the gradient. Gels were then left
to polymerize at room temperature, after which they could
be stored under moist conditions at 4°C refrigerator for no
longer than 1 week.
Electrophoresis
Preelectrophoresis (30minutes at 70 V) and electrophor-
esis were performed by using Tris, boric acid, and Na2-
EDTA (pH 8.4) as running buffer. Whole serum (50 μl)
was mixed with 25 μl of sucrose and a total volume of
10 μl of sample was applied to each well. The 10 μl of
reference proteins (HMW Calibration for Native Elec-
trophoresis, GE Healthcare UK Ltd., Buckinghamshire,
England) were run on gel. Wells closest to the edges of
the gel were not used. Electrophoresis was conducted at
70 V for 30 minutes, 100 V for 6 h and 200 V for 14 h.
Western blotting
After electrophoresis, plasma proteins and reference pro-
teins were electroretically transferred to PVDF mem-
branes, stained with 0.1% ponceau S, and the position of
reference protein bands labeled by pencil, and distained by
diffusion, the membrane was blocked with 5% BSA and
incubated with horseradish peroxidase-labeled goat anti-
human apoA-I-IgG polyclonal antibody which was pre-
pared at the apolipoprotein Research Laboratory, West
China Medical Center, Sichuan University overnight at
4°C. The membrane was washed three times. The relative
concentration of each subclass was calculated as the per-
centage of plasma apoA-I (%) according to the density of
each spot (BioRAD Imaging System Flier). The relative
concentration of each HDL subclasses was calculated as
the percentage of total plasma apoA-I according to the
density of each spot. Particle diameters of the HDL sub-
classes were assessed by comparing the mobility of the
sample with the mobility of calibration standard using a
standard curve that included thyroglobulin, ferritin, cata-
lase, lactate dehydrogenase, and bovine serum albumin
(HMW Calibration for Native Electrophoresis, GE Health-
care UK Ltd., Buckinghamshire, England). Then, the rela-
tive percent concentration of each HDL subclass wasmultiplied by the apoA-I concentration in the individual
samples, respectively, to yield the relative concentrations
of each HDL subclass of apoA-I (in mg/L). The inter-assay
variation (n =5) of the specific HDL subclasses was 9.6%
(Preβ1-HDL), 8.5% (HDL3c), 6.8% (HDL3b), 10.3% (HDL3a),
9.9% (HDL2a), and 8.3% (HDL2b+Preβ2-HDL), respectively.
The intra-assay variation (n= 5) of the specific HDL sub-
classes was 2.1% (Preβ1-HDL), 2.0% (HDL3c), 1.6%
(HDL3b), 2.4% (HDL3a), 2.3% (HDL2a), and 1.9% (HDL2b
+Preβ2-HDL), respectively.
Statistical analyses
Kolmogorov-Smirnov statistics was used to test normal-
ity of distributions of plasma lipids, lipoproteins, HDL
subclasses, and clinical parameters. For analysis, non-
Gaussian-distributed data were transformed using the
natural logarithm to approach a Gaussian distribution.
All values were presented as mean± S.D. The significant
differences between two groups were analyzed by t-test.
Pearson correlation analysis was used to estimate the as-
sociation between plasma parameters and the changes in
HDL subclasses profile among CHD with diabetes
patients. A multiple regression analysis was also pre-
formed the relationship between changes in coronary
stenosis, and plasma lipids, lipoproteins as well as the
contents of HDL subclasses. Differences were considered
significant at P< .05. All statistical analysis was per-
formed using the statistical package SPSS Version 15.0
(SPSS Inc).
Results
The one-dimensional gel electrophoresis and
immunodetection method
Figure 1 shows the distributions of HDL subclasses for
representative CHD and normolipidemic healthy subjects
by nondenaturing 1-dimensional gel electrophoresis and
immunodetection method. The high molecular protein
standards (lane 1), (lane 2) from healthy normolipidemic
subjects, (lane 3 and lane 4) from CHD subjects. With this
method, the HDL can be separated into 6 distinct sub-
classes, preβ1-HDL, HDL3c, HDL3b, HDL3a, HDL2a, and
HDL2b+ Preβ2, according to their particles size.
Figure 2 presented that the liner relationship between
the HDL subclasses [preβ1-HDL(r = .95) and HDL2b+preβ2
(r = .98)]determined by using 1D-PAGGE associated with
immunodection and those by using 2D-PAGGE associated
with immunodection is stronger.
Baseline characteristics and plasma lipid, apolipoprotein
along with HDL subclasses distribution Profiles in CHD
patients with and without diabetes
Plasma levels of FPG, TG, TC, LDL-C, apoB-100, and
the ratios of apoB-100 to apoA-I along with waist-to-hip
(WHR) as well as waist and Gensini Score were
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(−30%), apoA-I (−18%) were significantly lower in CHD
patients with diabetes (n = 115) in comparison with the
CHD patients without diabetes (n = 97; Table 1). The
body mass index (BMI), and Hip did not differ signifi-
cantly between the CHD patients with diabetes and the
CHD patients without diabetes.
What is more, plasma contents of large buoyant parti-
cles HDL2a and HDL2b+preβ2 were significantly decreased
but those of small dense HDL3 (HDL3b and 3a) were sig-
nificantly increased in CHD patients with diabetes com-
pared with CHD patients without diabetes.Correlation of plasma lipids, lipoproteins,
apolipoproteins, and HDL subclasses contents for CHD
patients with diabetes
As shown in Table 2, in CHD patients with diabetes,
plasma FPG, TG, and LDL-C levels, Gensini Score, BMI
as well as apoB-100/A-I ratio were positively correlated
with HDL3a, and HDL3b but inversely associated with
HDL2a, and HDL2b+preβ2. On the contrary, HDL-C levels
were negatively correlated with HDL3a and positively
correlated with HDL2a, HDL2b+preβ2 along with preβ1-Figure 1 High-density lipoprotein subclasses were separated
by nondenaturing 1-dimensional gel electrophoresis and
immuodetection. The high molecular protein standards (lane 1),
Normolipidemic healthy subjects (lane 2), CHD Patients (lane 3 and
lane 4).HDL. The apoA-I levels were related significantly to all
HDL subclasses contents.
Relationship of plasma lipids, lipoproteins,
apolipoproteins, and HDL Subclasses contents with the
gensini score by Multivariate Stepwise Regression
Analyses
To obtain a better understanding of the determinants
for CHD patients with diabetes, stepwise multivariate re-
gression analyses with the Gensini Score as dependent
variables, and plasma lipids, lipoproteins, apolipopro-
teins, and HDL subclasses as independent variables were
performed in this work (Table 3). The results revealed
that the Gensini Score was significantly and independ-
ently predicted by TC, apoB-100, and the large-sized
HDL2a along with HDL2b+preβ2.
Discussion
HDL is not a homogeneous category of lipoproteins but
consists of a set of distinct subclasses of particles that
vary in size, shape, density, surface charge, and compos-
ition. Nondenaturing polyacrylamide gradient gel elec-
trophoresis (PAGGE) has been used to isolate HDL
based on particle size. Human plasma HDL includes five
subclasses known as HDL2b, HDL2a, HDL3a, HDL3b, and
HDL3c in order of decreasing particle size [17]. Other
methods for measuring HDL subclasses, such as nuclear
magnetic resonance (NMR) spectroscopy, which
assumes the detected amplitudes of spectral signals
emitted by HDL subclasses of different size. This tech-
nique determines 5 subclasses of increasing size, HDL1,
2, 3, 4, and 5 corresponds to the HDL3c, 3b, 3a, 2a, 2b
according to the PAGGE [18]. Agarose gel electrophor-
esis separates HDL into α-, and preβ-mobility HDL,
according to their different charges [19]. By combining
agarose gel electrophoresis with nondenaturing PAGGE
(2D-PAGGE) along with immunodetection, preβ-HDL
can be further separated into preβ1-, and preβ2-HDL ex-
cept the α-HDL used to isolate 5 subclasses. In this
work, the characterization of HDL particle size (diam-
eter) by 1D-PAGGE along with immunodetection
method which developed and modified at our Labora-
tory. That defined 6 subclasses: preβ1-HDL, HDL3c,
HDL3b, HDL3a, HDL2a, and HDL2b+preβ2 (Figure 1). Preβ1-
HDL has an apparent molecular mass of 60–70 kDa and a
diameter of 5–6 nm [20]. Therefore, the preβ1-HDL can
be separated easily from the other HDL subclasses com-
ponents. On the other hand, because of the diameter of
preβ2-HDL(10.2–12.37 nm) was similar to that of HDL2b
(9.8–12.97 nm), they overlapped each other. In this con-
text, we used to add up the preβ2-HDL, HDL2b defined as
HDL2b+preβ2.
Meanwhile, we have investigated the plasma HDL
subclasses distribution in hyperlipidemic, and obese
Figure 2 The scatter chart of preβ1-HDL and HDL2b+preβ2 between in nondenaturing 1-dimensional and 2-dimensional gel
electrophoresis coupled with immuodetection methods.
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Table 1 Clinical and Biological Characteristic of CHD
Patients with Diabetes and CHD Patients without
Diabetes
CHD Patients with
Diabetes (n = 115)
CHD Patients without
Diabetes (n = 97)
Age(yr) 67.1 ± 9.7 63.7 ± 8.3
Female/Male 45/70 53/44
SBP(mmHg) 135.2 ± 20.6 130.8 ± 17.7
DBP(mmHg) 77.6 ± 8.4 75.7 ± 7.5
BMI(kg/m2) 25.0 ± 2.6 24.3 ± 2.1
Waist (cm) 92.4 ± 8.6 88.1 ± 7.8†
Hip (cm) 94.2 ± 6.4 93.1 ± 5.7
WHR 0.98 ± 0.1 0.94 ± 0.1†
Gensini Score 53.7 ± 9.2 22.9 ± 6.3†
FPG(mmol/L) 9.0 ± 1.2 5.2 ± 0.6{
TG(mmol/L) 2.2 ± 0.5 1.8 ± 0.6*
TC(mmol/L) 4.4 ± 1.1 3.9 ± 1.0*
LDL-C(mmol/L) 3.4 ± 1.0 2.7 ± 0.7†
HDL-C(mmol/L) 1.0 ± 0.2 1.3 ± 0.2†
ApoA-I(g/L) 1.1 ± 0.2 1.3 ± 0.3*
ApoB-100(g/L) 0.8 ± 0.2 0.6 ± 0.2*
ApoB-100/A-I 0.7 ± 0.2 0.5 ± 0.1*
Preβ1-HDL(mg/L) 92.0 ± 9.5 83.0 ± 7.0
HDL3c(mg/L) 83.9 ± 7.4 78.5 ± 6.9
HDL3b(mg/L) 170.2 ± 20.9 142.5 ± 18.2
*
HDL3a(mg/L) 310.5 ± 44.7 272.5 ± 38.1
*
HDL2a(mg/L) 190.5 ± 25.8 285.9 ± 42.2
{
HDL2b+Preβ2-HDL(mg/L) 311.9 ± 52.2 389.3 ± 69.5
{
CHD, coronary heart disease; BMI, body mass index; FPG, fasting plasma
glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein
cholesterol; HDL-C, high density lipoprotein cholesterol; ApoA-I,
apolipoproteinA-I; ApoB-100, apolipoprotein B-100.
Data are presented as Mean ± S.D.
*P< 0.05, †P< 0.01, {P< 0.001 vs CHD with diabetic patients.
Table 2 Assessment of Relationship between Plasma
Lipid, Lipoprotein, Apolipoprotein and HDL Subclasses
Contents in CHD Patients with Diabetes
Preβ1-HDL HDL3c HDL3b HDL3a HDL2a HDL2b+preβ2-HDL
FPG .160 .108 .390* .398* -.570** -.630**
TG .112 .208 .243* .291* -.305** -.369**
TC .099 .199 .192 .210* .030 .042
LDL-C .140 .120 .220* .150 -.252* -.271*
HDL-C .176* -.140 -.136 -.174* .302** .358**
Gensini Score .102 .134 .184* .211* -.234** -.263**
BMI .210 .231 .217 .256* -.244* -.270*
ApoA-I .430** .405** .453** .507** .575** .602**
ApoB-100 .116 .128 .133* .101 -.120 -.123
ApoB-100/A-I .240 .307* .365** .444** -.436** -.470**
CHD, coronary heart disease; FPG, fasting plasma glucose; TG, triglyceride; TC,
total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high
density lipoprotein cholesterol; BMI, body mass index; ApoA-I,
apolipoproteinA-I; ApoB-100, apolipoproteinB-100.
*P< .05, **P< .01.
Table 3 Correlations of HDL Subclasses Contents with









Gensini Score HDL2a -.499 .174 -.572 −2.856 .007
HDL2b -.522 .183 -.598 −2.872 .006
ApoB100 67.563 20.153 .677 2.495 .016
TC 28.304 8.183 .522 3.459 .001
CHD, coronary heart disease; TC, total cholesterol; HDL-C, high density
lipoprotein cholesterol; ApoB100, apolipoproteinB100.
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with immunodection [21-23] and found that the contents
of preβ2-HDL kept the relative constant among these sub-
jects (about 60 mg/L). Thus, the changes in contents of
HDL2b+preβ2 mainly reflect the alteration of HDL2b con-
tents. Moreover, relations of the preβ1-HDL and HDL2b
+preβ2 by using 1D-PAGGE associated with immunodection
and 2D-PAGGE associated with immunodection, respect-
ively were explored, and the results revealed that the preβ1-
HDL (r= .95) and HDL2b+preβ2 (r = .98) have a significant
liner correlation between in 1D-PAGGE associated with
immunodection and 2D-PAGGE associated with immuno-
dection measuring methods (Figure 2). The other HDL
subclasses contents in subjects with 1D-PAGGE associated
with immunodection were similar to those in subjects with
2D-PAGGE associated with immunodection (data not
shown). Based on above reasons, making use of the 1D-PAGGE associated with immunodection to classify the
HDL subclasses is simple and reliable.
Our study, conducted on a the CHD patients with or
without diabetes, confirmed the typical alterations of lipid
profile, i.e., low concentrations of HDL-C, increased levels
of TG, TC, LDL-C, and FPG in CHD patients with diabetes
as compared to CHD patients without diabetes. Meanwhile,
the data presented that diabetes was associated with a pro-
found remodel of HDL subclasses toward a less atheropro-
tective profile, with a reduction of the larger HDL2 (HDL2a
and HDL2b+preβ2) subclasses, and an increase of the smaller,
lipid poor HDL3 (HDL3b, and 3a) particles.
Compared and analyzed the prevalence of coronary artery
lesions according to the angiographic Gensini Score which
used to reflect the extent of coronary atherosclerosis, and
the data showed that in the group of CHD patients with
diabetes, the Gensini Score was significant higher than that
in the group of CHD patients without diabetes (53.7 vs
22.9). Regardless of in CHD patients with or without dia-
betes, the mean levels of plasma lipids, and lipoproteins
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guidelines) except the TG levels were border-line high and
HDL-C levels were low for CHD patients with diabetes;
whereas the contents of HDL2b+preβ2 (389.3 mg/L) were sig-
nificantly lower for the CHD patients without diabetes than
HDL2b added preβ2-HDL contents (378.4+ 56.0= 434.4
mg/L) for normolipidemic subjects [24]. Unlike this, we
have previously investigated the plasma HDL subclasses
distribution in hyperlipidemic, obese, primary diabetic
mellitus (DM), and CHD patients [22,23,25-27]. The
results showed that in these subjects, increased TG, TC,
LDL-C, and decreased HDL-C accompanied with an in-
crease of small-sized HDL particles and a reduction of
large-sized HDL particles successively.
DM is characterized by dyslipidemia, including increased
LDL-C levels, low HDL-C levels, and increased TG. Unlike
other lipoproteins, HDL are not formed as mature lipopro-
teins, but appears in plasma as precursor particles. In CHD
patients with diabetes, these subclasses undergo remodeling
and interconversion by the addition and removal of their
neutral lipids, phospholipids, and apo components due to
the alteration of plasma lipids levels.
Several enzymes and proteins involved in HDL metabol-
ism and remodeling are lecithin: cholesterol acyltransferase
(LCAT), cholesterol ester transfer protein (CETP), hepatic
lipase (HL) and lipoprotein lipase(LPL) and phospholipids
transfer protein (PLTP), the ATP-binding cassette trans-
porter A1(ABCA1) and G1(ABCG1). LCAT transfers the
sn-2-acyl group of lecithin to cholesterol, therefore results
in the generation of cholesterol esters, which are retained in
the core of HDL particles, leading to the conversion of dis-
coidal nascent HDL into spherical particles. CETP action
results in transfer of CE from HDL towards triglyceride-
rich lipoproteins (TRLs), and reciprocal transfer of TGs
from TRLs to HDL. Elevated TGs increase the CE transfer
process out of HDL, resulting in CE depletion and TG en-
richment of HDL and subsequent increased HDL catabol-
ism leads to the formation of small HDL particles [28]. LPL
is the rate-limiting enzyme for the hydrolysis of the TG core
of TRLs, chylomicrons (CM) and VLDL, when catabolized
by LPL, CM and VLDL release PL, apoA-I, cholesterol, TG,
and apoCs, subsequent binding of these products to HDL3
results in the formation of HDL2 particles [29]. ABCAI is
responsible for cholesterol and PL efflux towards lipid-poor
or lipid-free apoA-I [30]; ABCG1 mediates cholesterol and
PL efflux to mature HDL [31].
Most studies have established the action of above
enzymes and protein factors associated with the increase
of plasma TG, LDL-C, and decrease of plasma HDL-C
levels. Hence, based on the changed in plasma lipids
which leading to altered HDL subclass and particle size
remodel in CHD patients with diabetes [32,33].
Meanwhile, plasma LCAT and LPL activity has been
reported to be decreased in IR and T2DM subjects [34]. Adecreased post-heparin plasma LPL/HL ratio is a determin-
ant of low HDL2 cholesterol in IR. At the same time, Maul-
din et al [35] could demonstrate that macrophage ABCG1
expression and function are decreased in mouse models of
T2DM and ABCA1 gene expression is severely decreased
in the liver and pertitoneal macrophages of diabetic mice
compared with euglycemic control mice [36]. In addition,
PLTP activity in plasma is elevated in IR and T2DM in asso-
ciation with high plasma TG and obesity [37].
Compared with the CHD patients without diabetes, in
CHD patients with diabetes, the alteration of plasma
lipids levels and activities of enzymes involved in HDL
particles metabolism and the receptor mediated uptake
or efflux of free cholesterol(FC)/cholesterol esters(CE)
towards/from HDL is modified result in altered HDL
subclass and particle size.
The changes in HDL subclasses might correlate with
the WHR. The present data displayed that WHR is higher
significantly in CHD patients with diabetes (0.98), as com-
pared to CHD patients without diabetes (0.94). Some
studies demonstrated a negative relationship between
WHR and HDL2, independent of TG and other subclasses
[38]. This concords with studies by Terry et al [39] con-
cerning HDL2, although the latter did not correct for TG
and Walton et al [40] where TG were taken into account.
Type 2 diabetes is largely considered as a CHD
“equivalent” risk category [41] and the differences in
HDL subpopulations profile noted in diabetic women
resembled, both qualitatively and quantitatively, those
reported for male subjects with a previous CHD event
[42]. Taken together these findings suggest that early
alterations in HDL subpopulations profile may contrib-
ute to CHD risk in diabetic patients.
It was demonstrated that atorvastatin was more effective
to treat lipid abnormalities and to modify the HDL sub-
classes profile than simvastatin, by increasing the concen-
tration of the large, cholesterol rich, HDL2 and decreasing
the concentration of the small, TG-rich, HDL3 in CHD
patients [43]. In our study, nevertheless statins therapy
could be effective in normalizing the plasma lipids pheno-
type, the HDL particle size tend to small in CHD patients
with or without diabetes, particularly in CHD patients with
diabetes. That implicated that the distribution of HDL sub-
classes modification lagged behind the improvement of
plasma lipids levels. For the possible reason, on one side
might involve in the conversion process of HDL subclasses.
On the other side, it is well known that the treatment of
statins had significantly effect in modulating the athero-
genic lipids; but the impact of it on plasma lipoproteins me-
tabolism is unclear, and we speculated that the
compositions of plasma lipoproteins change could play a
function in these, and need to further study. Meanwhile,
the Pearson correlation and multivariate stepwise regression
analysis supported that the Gensini Score were associated
Tian et al. Lipids in Health and Disease 2012, 11:54 Page 8 of 9
http://www.lipidworld.com/content/11/1/54independently with HDL subclasses. Under this condition,
our findings implication that the distribution of HDL sub-
classes abnormalities might be an important potential factor
involved in the increased CHD risk associated with diabetic
patients and arteriographic progression.
In present study, we mainly discussed the HDL
subclass profiles and alterations of particle size in
CHD patients with diabetes or without diabetes. The
limitation of the present work is that no baseline
measurements of lipids prior to beginning statin ther-
apy, and potential mechanisms underlying the proces-
sing and/or distribution difference in HDL subclasses
particles should be discussed in next study.
Conclusions
To summarize, the abnormality of HDL subpopulations
distribution and particle size may contribute to CHD risk
in diabetic patients. The HDL subclasses distribution
may help in severity of coronary artery and risk stratifica-
tion, especially in CHD patients with therapeutic LDL,
TG and HDL levels.
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